Your Search Returned 500 tagged news reports
Reference lists are much longer (which surely reflects both the sie of the literature and the relative ease of bibliography compared to the bound-volume/index card days). Francois-Xavier Coudert, the blog's author, says that he'll be putting up some
Next Ian will be seeking more innovation....just CEO speak without specifics Permalink to Comment good point on February 20, 2014 10:16 AM writes... that is long time due. Permalink to Comment good point on February 20, 2014 10:16 AM writes... that
Permalink to Comment Anonymous on February 13, 2014 11:26 AM writes... You are incredibly restrained when you write these posts, Derek. I occasionally comment on your blog about the need for change in this industry. The big pharma model is dead in
Puff the Mutant Dragon on January 23, 2014 11:54 AM writes.....Permalink to Comment Anonymous on January 23, 2014 12:31 PM writes.....As a chemical biologist, I'd be wary of using anything with more than a single lesion, and it seems to me that the
I love these fake soul-searching moments, having witnessed several of them firsthand when I was at Lilly. The financial rewards to prescriber payola and off-label marketing are so strong that public shaming and/or legal crackdowns are the only hope.
Here's a roundup of the top chem-blog posts of the year, as picked by Nature 's Sceptical Chymist blog...Permalink to Comment Anonymous on December 11, 2013 11:49 AM writes.....Permalink to Comment Anonymous on December 11, 2013 11:55 AM writes.
Here's a look at where the biopharma companies really congregate, courtesy of Luke Timmerman at Xconomy. There's also a revealing comparison to the situation ten years ago. His cutoff is for a company to have at least $100 million in cash (and short
Mays Academy in Chicago to insure the safety of students on the first day of school. (Chris Walker, Chicago Tribune) City watchful, wary as CPS 6:56 a.m...Mays Academy in the Englewood neighborhood on the first day of school. (Chris Walker, Chicago
Here's a provocative post over at Chemjobber's blog, taking off from a letter to C&E News . James Collmann (emeritus at Stanford) wrote in about a recent article on Chinese scientists returning to that country to take academic positions. He mentions,
The only people whose good fortune is certain from this are the lawyers of the people who bought the options. I'm not guessing so, but I wonder if the ratio of calls to puts looked the same on the high-volume days as the low-volume ones...Judging by